Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

May’s top stories: ProMedica began human stem cell trial, Cerulean dosed in Phase l/ll combination trial

ProMedica and Stemedica planned to begin a human stem cell trial for traumatic brain injury and Cerulean dosed its first patient in a Phase l/ll combination trial of CRLX101 and lynparza. Drugdevelopment-technology.com wraps up the key headlines from May 2016.

Go Top